pd168393 and paclitaxel

pd168393 has been researched along with paclitaxel in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Guan, JY; Hour, TC; Hsieh, MW; Huang, CY; Lin, CC; Lin, SR; Liu, GY; Pu, YS; Wang, CW	1

Other Studies

1 other study(ies) available for pd168393 and paclitaxel

Article	Year
Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. Biochemical pharmacology, 2006, Mar-14, Volume: 71, Issue:6 Topics: Adenocarcinoma; Androgens; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Male; Paclitaxel; Prostatic Neoplasms; Quinazolines	2006

Article

Year

Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.

Biochemical pharmacology, 2006, Mar-14, Volume: 71, Issue:6

Topics: Adenocarcinoma; Androgens; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Male; Paclitaxel; Prostatic Neoplasms; Quinazolines

2006